Loading
Latest filing published 11 Oct 2023 for Zynerba Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Albert P. Parker (senior executive) discloses dealings in Zynerba Pharmaceuticals, Inc. to SEC (Form 4). The record holds 6 filings, for trades running from 14 February 2022 to 10 October 2023.
No open-market purchase appears, only 1 sale worth €1,601. The rest of the record consists of 4 share grants. Since January 2023: no purchases and 1 sale on the market.
Most recently, on 11 October 2023, the filings show a transaction in Zynerba Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations